308 related articles for article (PubMed ID: 30362020)
21. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party.
Penack O; Peczynski C; Koenecke C; Polge E; Sanderson R; Yakoub-Agha I; Fegueux N; Daskalakis M; Collin M; Dreger P; Kröger N; Schanz U; Bloor A; Ganser A; Besley C; Wulf GG; Novak U; Moiseev I; Schoemans H; Basak GW; Chabannon C; Sureda A; Glass B; Peric Z
Front Immunol; 2023; 14():1252811. PubMed ID: 37828980
[TBL] [Abstract][Full Text] [Related]
22. Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
Martín-Martín L; Gutiérrez-Herrero S; Herrero-García M; Martín García-Sancho A; Yeguas A; Martín-López AÁ; López-Corral L; Pérez-López E; García-Blázquez M; Sánchez-Guijo F; Vidriales MB; Gaipa G; ; ; Orfao A
Blood Cancer J; 2024 May; 14(1):83. PubMed ID: 38760376
[No Abstract] [Full Text] [Related]
23. Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma.
Saha A; Jhaveri K; Sarfraz H; Chavez JC
Expert Opin Biol Ther; 2023; 23(9):869-876. PubMed ID: 37599463
[TBL] [Abstract][Full Text] [Related]
24. Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma.
Yu T; Luo C; Zhang H; Tan Y; Yu L
Front Immunol; 2023; 14():1139482. PubMed ID: 37449207
[TBL] [Abstract][Full Text] [Related]
25. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder BJ; Kurtz DM; Alig SK; Frank MJ; Shukla N; Garofalo A; Macaulay CW; Shahrokh Esfahani M; Olsen MN; Hamilton J; Hosoya H; Hamilton M; Spiegel JY; Baird JH; Sugio T; Carleton M; Craig AFM; Younes SF; Sahaf B; Sheybani ND; Schroers-Martin JG; Liu CL; Oak JS; Jin MC; Beygi S; Hüttmann A; Hanoun C; Dührsen U; Westin JR; Khodadoust MS; Natkunam Y; Majzner RG; Mackall CL; Diehn M; Miklos DB; Alizadeh AA
Cancer Cell; 2023 Jan; 41(1):210-225.e5. PubMed ID: 36584673
[TBL] [Abstract][Full Text] [Related]
26. Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma.
Newsam AD; Coughlin CA; Trabolsi A; Schatz JH
Leuk Lymphoma; 2023 Dec; 64(14):2217-2224. PubMed ID: 37933565
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
Crombie JL; Jacobson CA; Redd R; Shouse G; Herrera AF; Chow VA; Gauthier J; Mullane E; Cahill K; Kline J; Romancik J; Cohen JB; Saucier A; Houot R; Armand P; Hess B
Haematologica; 2023 Dec; 108(12):3433-3437. PubMed ID: 37259597
[No Abstract] [Full Text] [Related]
28. CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach.
Dreger P; Corradini P; Gribben JG; Glass B; Jerkeman M; Kersten MJ; Morschhauser F; Mussetti A; Viardot A; Zinzani PL; Sureda A;
Lancet Haematol; 2023 Dec; 10(12):e1006-e1015. PubMed ID: 38030311
[TBL] [Abstract][Full Text] [Related]
29. The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity.
Galli E; Bellesi S; Pansini I; Di Cesare G; Iacovelli C; Malafronte R; Maiolo E; Chiusolo P; Sica S; Sorà F; Hohaus S
Br J Haematol; 2023 Nov; 203(4):564-570. PubMed ID: 37789569
[TBL] [Abstract][Full Text] [Related]
30. High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy.
Jin J; Lin L; Meng J; Jiang L; Zhang M; Fang Y; Liu W; Xin X; Long X; Kuang D; Ding X; Zheng M; Zhang Y; Xiao Y; Chen L
Mol Ther; 2024 May; 32(5):1252-1265. PubMed ID: 38504519
[TBL] [Abstract][Full Text] [Related]
31. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract][Full Text] [Related]
32. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
Jain MD; Ziccheddu B; Coughlin CA; Faramand R; Griswold AJ; Reid KM; Menges M; Zhang Y; Cen L; Wang X; Hussaini M; Landgren O; Davila ML; Schatz JH; Locke FL; Maura F
Blood; 2022 Aug; 140(5):491-503. PubMed ID: 35476848
[TBL] [Abstract][Full Text] [Related]
33. CAR-T cell therapy: unravelling its potential in extra-nodal diffuse large B cell lymphoma.
Khan SJ; Alhaj Moustafa M
Chin Clin Oncol; 2024 Apr; 13(2):31. PubMed ID: 38644547
[No Abstract] [Full Text] [Related]
34. A single-cell atlas of CD19 chimeric antigen receptor T cells.
Li X; Henderson J; Gordon MJ; Sheikh I; Nastoupil LJ; Westin J; Flowers C; Ahmed S; Wang L; Neelapu SS; Strati P; Deng Q; Green MR
Cancer Cell; 2023 Nov; 41(11):1835-1837. PubMed ID: 37738975
[TBL] [Abstract][Full Text] [Related]
35. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Andreadis B; Bartlett NL; Budde LE; Caimi PF; Chang JE; Christian B; DeVos S; Dholaria B; Fayad LE; Habermann TM; Hamid MS; Hernandez-Ilizaliturri F; Hu B; Kaminski MS; Karimi Y; Kelsey CR; King R; Krivacic S; LaCasce AS; Lim M; Messmer M; Narkhede M; Rabinovitch R; Ramakrishnan P; Reid E; Roberts KB; Saeed H; Smith SD; Svoboda J; Swinnen LJ; Tuscano J; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2023 Nov; 21(11):1118-1131. PubMed ID: 37935098
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of premanufacture CD8
Wang Y; Tong C; Lu Y; Wu Z; Guo Y; Liu Y; Wei J; Wang C; Yang Q; Han W
Signal Transduct Target Ther; 2023 Oct; 8(1):409. PubMed ID: 37875502
[TBL] [Abstract][Full Text] [Related]
37. Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders.
Bachanova V; Nachman PH
Bone Marrow Transplant; 2023 Nov; 58(11):1175-1176. PubMed ID: 37598289
[No Abstract] [Full Text] [Related]
38. Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report.
Li C; Zhang X; Zhu D; Bu X; Wang L; Zhao P
Ann Hematol; 2023 Dec; 102(12):3625-3627. PubMed ID: 37608197
[No Abstract] [Full Text] [Related]
39. Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737-2746.
Blood; 2023 Feb; 141(6):683. PubMed ID: 36757722
[No Abstract] [Full Text] [Related]
40. NICE approves routine NHS use of CAR-T for diffuse large B-cell lymphoma.
Wilkinson E
Lancet Oncol; 2023 Mar; 24(3):208. PubMed ID: 36739880
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
